

Press Release

13th August 2021, Ludhiana

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of pharmaceutical (APIs) and specialty chemicals today posted its financial results for the quarter ending 30th June 2021. The Company on QoQ & YoY basis recorded 12% growth in total income, however the EBITDA has been almost flat on QoQ and declined by about 27% on YoY basis on account of stressed demand primarily due to 2nd wave of Covid-19 globally.

June 2021 vis a vis March 2021:

Particulars	Quarter ended	
	30.06.2021	31.03.2021
Total income	524	467
EBIDTA	116	117
Profit before Tax	90	106
Profit after Tax	67	75
EPS in Rupees	11.41	12.76

Rs Crore

June 2021 vis a vis June 2020:

Particulars	Quarter ended	
	30.06.2021	30.06.2020
Total income from operations	524	466
EBIDTA	116	158
Net Profit before Tax	90	147
Net Profit after Tax	67	128
EPS in Rupees	11.41	22.30

Rs Crore

Dr Sanjay Chaturvedi, Chief Executive Officer said "During the quarter ended June 2021, the Company's performance has been satisfactory in spite of difficult operating conditions faced by the Company during surged situation of Covid-19 pandemic. The Chemicals segment performed very well during the quarter both in terms of top line and bottom line.

He also added, the Company completed the installation of new manufacturing facilities 'Unit -10' to manufacture multiple Pharma (API's) products including Fenofibrate, Lamotrigine and Ursodeoxycholic Acid (UDCA) to cater the growing demand.

Talking about future projects, he added that the installation of new manufacturing facilities 'Unit -9' for manufacturing Gabapentin & other pharma (APIs) products is slightly delayed

of its schedule due to 2nd wave of Covid-19 and expected to complete in 3rd quarter of FY22 without any cost overrun.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164) is one of the leading pharmaceutical (APIs) Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.